168 related articles for article (PubMed ID: 30509115)
1. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
[TBL] [Abstract][Full Text] [Related]
2. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
3. Biomarker Development for Intraductal Papillary Mucinous Neoplasms Using Multiple Reaction Monitoring Mass Spectrometry.
Kim Y; Kang M; Han D; Kim H; Lee K; Kim SW; Kim Y; Park T; Jang JY; Kim Y
J Proteome Res; 2016 Jan; 15(1):100-13. PubMed ID: 26561977
[TBL] [Abstract][Full Text] [Related]
4. An elevated CA 19-9 is associated with invasive cancer and worse survival in IPMN.
Ciprani D; Morales-Oyarvide V; Qadan M; Hank T; Weniger M; Harrison JM; Rodrigues C; Horick NK; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Pancreatology; 2020 Jun; 20(4):729-735. PubMed ID: 32332003
[TBL] [Abstract][Full Text] [Related]
5. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
6. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
O'Neill RS; Emmanuel S; Williams D; Stoita A
World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
[TBL] [Abstract][Full Text] [Related]
7. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer.
Ilies M; Sappa PK; Iuga CA; Loghin F; Gesell Salazar M; Weiss FU; Beyer G; Lerch MM; Völker U; Mayerle J; Hammer E
Clin Chim Acta; 2018 Feb; 477():127-134. PubMed ID: 29221926
[TBL] [Abstract][Full Text] [Related]
8. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
10. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer.
Nakano R; Nishiumi S; Kobayashi T; Ikegawa T; Kodama Y; Yoshida M
Biomark Med; 2020 Jul; 14(11):1009-1020. PubMed ID: 32940075
[No Abstract] [Full Text] [Related]
11. Circulating Leptin and Branched Chain Amino Acids-Correlation with Intraductal Papillary Mucinous Neoplasm Dysplastic Grade.
Yip-Schneider MT; Simpson R; Carr RA; Wu H; Fan H; Liu Z; Korc M; Zhang J; Schmidt CM
J Gastrointest Surg; 2019 May; 23(5):966-974. PubMed ID: 30215202
[TBL] [Abstract][Full Text] [Related]
12. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
13. Main pancreatic duct dilation greater than 6 mm is associated with an increased risk of high-grade dysplasia and cancer in IPMN patients.
Ateeb Z; Valente R; Pozzi-Mucelli RM; Malgerud L; Schlieper Y; Rangelova E; Fernandez-Moro C; Löhr JM; Arnelo U; Del Chiaro M
Langenbecks Arch Surg; 2019 Feb; 404(1):31-37. PubMed ID: 30612152
[TBL] [Abstract][Full Text] [Related]
14. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
[TBL] [Abstract][Full Text] [Related]
15. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated With Invasive Intraductal Papillary Mucinous Carcinoma of the Pancreas.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yanagisawa A; Yamaue H
JAMA Surg; 2017 Mar; 152(3):e165054. PubMed ID: 28122068
[TBL] [Abstract][Full Text] [Related]
17. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
[TBL] [Abstract][Full Text] [Related]
18. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
19. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
20. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
